Immunologic Response to Secukinumab in Plaque Psoriasis

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT02592018
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.

Study Details

This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.

Key Dates

Start date
Oct 31, 2016
Status verified
Aug 2020
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Secukinumab
    All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.

Primary Outcome Measure

Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline [ Time Frame: Baseline to Week 2 ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Psoriasis and Skin Treatment CenterSan FranciscoCalifornia94118-

Find similar trials in San Francisco, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
UCSF Psoriasis and Skin Treatment Center· San Francisco, CA

Related Studies